Kenneth
Moderna Co-Founder Kenneth Chien’s New Biotech Secures $950M RNA Deal with Etherna
Kenneth Chien, Moderna, Etherna, RNA deal, biotech, mRNA therapies
BenevolentAI Embarks on Strategic Overhaul to Realign with Founding TechBio Mission
BenevolentAI, strategic overhaul, TechBio mission, artificial intelligence, biopharmaceutical development, drug discovery, Kenneth Mulvany